论文部分内容阅读
目的研究缬沙坦分散片联合苯磺酸左旋氨氯地平片治疗新发高血压患者的临床疗效。方法 40例新发的原发性高血压患者,随机分成A组和B组,各20例。A组采用缬沙坦分散片联合苯磺酸左旋氨氯地平片治疗,B组单用苯磺酸左旋氨氯地平片治疗,分别在治疗前及治疗1、2个月后测定患者的血压,同时观察治疗过程中两组出现的不良反应。结果两组治疗前收缩压和舒张压比较差异无统计学意义(P>0.05);A组在治疗1、2个月后收缩压低于治疗前,差异有统计学意义(P<0.05),舒张压虽然有较明显的下降,但差异无统计学意义(P>0.05)。B组治疗1、2个月后收缩压和舒张压与治疗前比较差异无统计学意义(P>0.05)。治疗后A组收缩压和舒张压均低于B组,但差异无统计学意义(P>0.05)。A组未出现不良反应,B组出现1例头晕头痛,不良反应发生率为5.0%;两组不良反应发生率比较差异无统计学意义(χ2=1.03,P>0.05)。结论缬沙坦联合苯磺酸左旋氨氯地平片能够有效降低新发高血压患者的血压,不良反应较少,临床效果值得肯定。
Objective To study the clinical efficacy of valsartan dispersible tablets combined with levamlodipine besylate in the treatment of newly diagnosed hypertensive patients. Methods Forty patients with newly diagnosed essential hypertension were randomly divided into A group and B group, 20 cases each. Group A was treated with valsartan dispersible tablets combined with levamlodipine besylate, group B was treated with levamlodipine besylate alone, and the patients’ blood pressure was measured before treatment and 1,2 months after treatment, respectively. At the same time, we observed the adverse reactions of two groups during the course of treatment. Results There was no significant difference in systolic blood pressure and diastolic blood pressure between the two groups before treatment (P> 0.05). The systolic blood pressure in group A was lower than that before treatment after 1 and 2 months (P <0.05) Although there was a significant decrease in pressure, the difference was not statistically significant (P> 0.05). The systolic blood pressure and diastolic blood pressure in group B after treatment for 1 and 2 months were not significantly different from those before treatment (P> 0.05). After treatment, systolic and diastolic blood pressure of group A were lower than that of group B, but the difference was not statistically significant (P> 0.05). There was no adverse reaction in group A, 1 case of dizziness and headache in group B, and the incidence of adverse reactions was 5.0%. There was no significant difference in the incidence of adverse reactions between the two groups (χ2 = 1.03, P> 0.05). Conclusions Valsartan combined with levamlodipine besylate can effectively reduce the blood pressure of patients with new-onset hypertension with fewer adverse reactions and the clinical effect is worthy of confirmation.